

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY

\_\_\_\_\_  
HELSINN HEALTHCARE, S.A. and  
ROCHE PALO ALTO, LLC,

Plaintiffs,

-vs-

DR. REDDY'S LABORATORIES, LTD.,  
DR. REDDY'S LABORATORIES, INC.,  
TEVA PHARMACEUTICALS USA, INC.,  
and TEVA PHARMACEUTICAL  
INDUSTRIES, LTD.

Defendants.

CIVIL ACTION NUMBER:

11-3962

TRIAL

\_\_\_\_\_  
Clarkson S. Fisher United States Courthouse  
402 East State Street  
Trenton, New Jersey 08608  
June 8, 2015

**B E F O R E:**

THE HONORABLE MARY L. COOPER  
UNITED STATES DISTRICT JUDGE

Certified as True and Correct as required by Title 28, U.S.C.,  
Section 753

/S/ Regina A. Berenato-Tell, CCR, CRR, RMR, RPR  
/S/ Carol Farrell, CCR, CRR, RMR, CCP, RPR, RSA

Dr. Reddy's Laboratories, Ltd., et al.  
v.  
Helsinn Healthcare S.A. et al

1 UNITED STATES DISTRICT COURT  
2 FOR THE DISTRICT OF NEW JERSEY

3 \_\_\_\_\_  
4 HELSINN HEALTHCARE, S.A. and  
5 ROCHE PALO ALTO, LLC,

6 Plaintiffs,

7 -vs-

8 DR. REDDY'S LABORATORIES, LTD.,  
9 DR. REDDY'S LABORATORIES, INC.,  
10 TEVA PHARMACEUTICALS USA, INC.,  
11 and TEVA PHARMACEUTICAL  
12 INDUSTRIES, LTD.

13 Defendants.

14 \_\_\_\_\_  
15 Clarkson S. Fisher United States Courthouse  
16 402 East State Street  
17 Trenton, New Jersey 08608  
18 June 8, 2015

19 **B E F O R E:**

20 THE HONORABLE MARY L. COOPER  
21 UNITED STATES DISTRICT JUDGE

22  
23 Certified as True and Correct as required by Title 28, U.S.C.,  
24 Section 753

25 /S/ Regina A. Berenato-Tell, CCR, CRR, RMR, RPR

/S/ Carol Farrell, CCR, CRR, RMR, CCP, RPR, RSA

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

A P P E A R A N C E S:

PAUL HASTINGS

BY: JOSEPH O'MALLEY, ESQUIRE  
ERIC W. DITTMANN, ESQUIRE  
ISAAC S. ASHKENAZI, ESQUIRE

SAUL EWING

BY: CHARLES M. LIZZA, ESQUIRE  
Attorneys for the Plaintiffs

BUDD LARNER

BY: STUART D. SENDER, ESQUIRE  
MICHAEL H. IMBACUAN, ESQUIRE  
HUA HOWARD WANG, ESQUIRE  
CONSTANCE S. HUTTNER, ESQUIRE  
KENNETH E. CROWELL, ESQUIRE

Attorneys for the Defendant, Dr. Reddy's Laboratories

WINSTON & STRAWN

BY: JOVIAL WONG, ESQUIRE  
GEORGE LOMBARDI, ESQUIRE  
JULIA MANO JOHNSON, ESQUIRE  
BRENDAN F. BARKER, ESQUIRE  
LITE DePALMA, GREENBERG, LLC  
BY: MAYRA V. TARANTINO, ESQUIRE  
Attorneys for the Defendant, Teva

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25

I N D E X

WITNESS                      VOIR    DIRECT    CROSS    REDIRECT    RECROSS  
   DIRE

David G. Frame  
By Mr. Imbacuan  
By Mr. Ashkenazi

1 BY MR. IMBACUAN:

2 Q. Dr. Frame, Chelly is also a study concerning the use of  
3 palonosetron for PONV. So how do the findings relate to the  
4 use of palonosetron for CINV?

5 A. Right. So you can't make an absolute direct correlation  
6 because PONV and CINV, as I explained earlier, are different  
7 entities. Okay?

8 Now, historically, we had studies with ondansetron,  
9 dolasetron and granisetron in both PONV and CINV, PONV and  
10 CINV. And, in general, it usually was about 2- to 10-fold  
11 higher dose for CINV than it was for PONV. But you really  
12 have to do the trials in CINV to get the absolute dose because  
13 it's a fairly broad range.

14 But the more potent the drug was, the less conversion  
15 that you actually needed because, again, the more potent that  
16 drug is, it can -- it binds to those receptors really, really,  
17 really strongly, right? Usually more potent has very high  
18 affinity so they bind to the receptors very strongly. And so  
19 the lower the dose that's usually required with the more  
20 potent drug, it wasn't as big of a conversion.

21 THE COURT: Between --

22 THE WITNESS: Between --

23 THE COURT: -- CINV and PONV?

24 THE WITNESS: Correct.

25 THE COURT: Or vice versa?

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.